Epilepsy (EP) is a type of chronic brain disease characterized by transient central nervous system malfunction which is the result of neuron paradoxical discharge in the brain. In a recent study, we evaluated the neuroprotective effect of α-lipoic acid on pentetrazol-induced rats. Epileptic rats were induced by intraperitoneal injection of pentetrazol (35 mg kg−1), and were intragastrically administered with α-lipoic acid for a month. The treatment with α-lipoic acid significantly reduced the total frequency of epileptic seizures and improved the behavior impairment and cognitive disorder caused by pentetrazol toxicity. With the administration of α-lipoic acid, not only did the apoptosis rate of nerve cells decrease, but also the formation of nitric oxide and malondialdehyde was inhibited. We also recorded evidence suggesting the treatment of α-lipoic acid could enhance the activity of antioxidant enzymes. Furthermore, in the hippocampus area of the brain, α-lipoic acid treatment promoted the translocation of Nrf2 in the nuclear fraction and increased the expression of HO-1 and NQO1. Our data indicated that α-lipoic acid may be a potential candidate for lessening the number of epileptic attacks, improving the behavior and cognitive disorder and cutting down the apoptosis rate of nerve cells in a pentetrazol-induced rat model through activating the Nrf2 signaling pathway.
(A) Chemical structure of apigenin. (B) Graph illuminating the experimental design for the time course of fructose and apigenin administration, and the timelines for the histological studies, biochemical analysis and western blot analysis.
Objective: Targeting the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway represents a promising therapeutic strategy for multiple sclerosis (MS). However, approved drugs like dimethyl fumarate (DMF) often induce severe side effects. This study investigated the natural flavonoid luteolin (LUT) as a potential dietary supplement alternative to DMF in a cuprizone (CPZ)-induced demyelination mouse model of MS.Methods: Mice were randomly assigned to five groups: control, CPZ model, CPZ+DMF (15 mg/kg), CPZ+LUT (25 mg/kg), and CPZ+LUT (50 mg/kg). Motor coordination and spatial memory were assessed via rotarod and Morris water maze tests. Myelin integrity was evaluated by Luxol fast blue staining and myelin basic protein (MBP) immunofluorescence/Western blot. Oxidative stress was measured by assessing superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) activities and malondialdehyde (MDA) levels. Nrf2 pathway activation was analyzed by nuclear translocation of Nrf2 and expression of downstream proteins (HO-1, NQO1) via Western blot. Molecular docking simulated interactions between compounds and the Keap1 protein.Results: LUT treatment significantly restored motor coordination and spatial memory, with efficacy comparable to DMF. It promoted MBP expression, attenuated oxidative damage by modulating SOD, CAT, GSH-Px, and MDA levels, and preserved myelin integrity. Furthermore, LUT markedly facilitated Nrf2 nuclear translocation and upregulated HO-1 and NQO1 expression. Molecular docking indicated that LUT possessed stronger binding affinity to the target protein Keap1 and a lower potential for off-target toxicity compared to the primary active metabolite of DMF.Conclusion: Luteolin exerts significant neuroprotective effects, primarily via Nrf2 pathway activation, with efficacy parallel to DMF but a superior safety profile. These findings identify LUT as a promising natural compound, bridging functional foods and MS therapy, and provide a foundation for developing LUT-enriched dietary regimens as an adjunct treatment strategy for MS.